Latest Trials Latest NewsFAQ

STANFORD UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1885-11-11

Employees: 10K

Market Cap: -

Website: http://www.stanford.edu

Clinical Trials

A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

Not Applicable

Completed

Conditions: Leukemia
Amyloidosis

Interventions: Drug: Lenalidomide
Drug: Melphalan
Drug: Dexamethasone

First Posted Date: 2009-04-30

Last Posted Date: 2017-03-22

Lead Sponsor: Stanford University

Target Recruit Count: 25

Registration Number: NCT00890552

Locations: 🇺🇸
Stanford University Cancer Institute, Stanford, California, United States

Effect of Preoperative Pupil Size on Quality of Vision After Wavefront-Guided LASIK

Phase 4

Completed

Conditions: Myopia

Interventions: Procedure: LASIK

First Posted Date: 2009-04-29

Last Posted Date: 2009-04-29

Lead Sponsor: Stanford University

Target Recruit Count: 51

Registration Number: NCT00889941

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Development of Algorithms for a Hypoglycemic Prevention Alarm: Closed Loop Study

Not Applicable

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Device: Predictive Low Glucose Suspend Algorithm ON
Device: Predictive Low Glucose Suspend Algorithm OFF

First Posted Date: 2009-04-21

Last Posted Date: 2018-02-28

Lead Sponsor: Stanford University

Target Recruit Count: 20

Registration Number: NCT00884611

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, Colorado, United States

Study of Treatment for Adolescents With Bulimia Nervosa

Not Applicable

Completed

Conditions: Bulimia

Interventions: Behavioral: Cognitive Behavioral Therapy for Adolescents
Behavioral: Supportive Psychotherapy
Behavioral: Family Based Therapy for Bulimia Nervosa

First Posted Date: 2009-04-09

Last Posted Date: 2015-05-25

Lead Sponsor: Stanford University

Target Recruit Count: 130

Registration Number: NCT00879151

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Chorioamnionitis

Phase 2

Completed

Conditions: Chorioamnionitis

Interventions: Drug: Ampicillin/gentamicin
Drug: Unasyn

First Posted Date: 2009-04-09

Last Posted Date: 2018-05-18

Lead Sponsor: Stanford University

Target Recruit Count: 92

Registration Number: NCT00879190

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.

Phase 2

Completed

Conditions: Venous Thrombosis

Interventions: Drug: Enoxaparin

First Posted Date: 2009-04-09

Last Posted Date: 2016-12-16

Lead Sponsor: Stanford University

Target Recruit Count: 11

Registration Number: NCT00878826

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Treatment of Psychotic Major Depression With Mifepristone

Phase 3

Terminated

Conditions: Affective Disorders, Psychotic
Depressive Disorder

Interventions: Drug: Mifepristone (RU-486)
Drug: Placebo

First Posted Date: 2009-03-23

Last Posted Date: 2017-04-04

Lead Sponsor: Stanford University

Target Recruit Count: 10

Registration Number: NCT00867360

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Low Dose Naltrexone for the Treatment of Juvenile Primary Fibromyalgia Syndrome

Not Applicable

Withdrawn

Conditions: Fibromyalgia

First Posted Date: 2009-03-05

Last Posted Date: 2015-12-11

Lead Sponsor: Stanford University

Registration Number: NCT00855972

Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)

Phase 2

Completed

Conditions: Prostatic Neoplasms

First Posted Date: 2009-03-04

Last Posted Date: 2010-06-03

Lead Sponsor: Stanford University

Target Recruit Count: 99999

Registration Number: NCT00855647

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

Phase 2

Completed

Conditions: Carcinoma, Renal Cell
Kidney Disease
Kidney Cancer

Interventions: Drug: Sorafenib

First Posted Date: 2009-03-03

Last Posted Date: 2015-06-19

Lead Sponsor: Stanford University

Target Recruit Count: 9

Registration Number: NCT00854620

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy